InnaVirVax nabs $4.9M in B round to advance HIV immunotherapy

French biotech InnaVirVax has rallied investors to pump $4.9 million into its coffers via a Series B round of financing. The company will use the proceeds to begin trials of its drug VAC-3S, which is intended to boost the immune systems of HIV-infected patients. Investors in the round included lead backers Fa Dièse and Fonds Régional de Co-Investissement d'Ile-de-France, along with contributions from CapDecisif 2 and G1J Ile-de-France. "Thanks to them, we will be able to carry out the first in man study with our VAC-3S immunotherapy, for which we received the authorization from the AFSSAPS (the French Drug Agency)," InnaVirVax CEO Joël Crouzet explained in a statement. "Based on a cutting edge discovery aiming at protecting the immune system in HIV-infected patients, this candidate immunotherapy represents a fantastic challenge and we think that it should be an effective therapeutic answer for patients at different stages of the disease." Release

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.